project_name: "Madrigal Equity Research â€“ Educational Project"
ticker: "MDGL"
company_name: "Madrigal Pharmaceuticals"
primary_indication: "Metabolic dysfunction associated steatohepatitis (MASH, formerly NASH)"
lead_asset: "Rezdiffra (resmetirom)"
disclaimer: "Educational and portfolio purposes only; not investment advice."
version: "0.1.0"
created_by: "Your Name Here"
python_min_version: "3.10"
